Literature DB >> 23257402

Increased incidence of herpes zoster among patients with systemic lupus erythematosus.

E F Chakravarty1, K Michaud, R Katz, F Wolfe.   

Abstract

Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection. The incidence of HZ may be increased in some autoimmune diseases, including systemic lupus erythematosus (SLE). We examined the incidence and risk factors for HZ in a prospective cohort of patients with physician-diagnosed SLE compared to those diagnosed with non-inflammatory musculoskeletal conditions (MSK). After excluding participants with a history of prior HZ at enrollment, we followed 1485 SLE patients and 2775 MSK with semi-annual mailed questionnaires for incident HZ between 2001 and 2010. Age-adjusted incidences were calculated for each group and Cox proportional hazard models were used to identify predictors of HZ. Zostavax® vaccination rates were compared between groups. Participants had a mean age of 60 years at enrollment, with 13.9 years of disease. SLE patients had more HZ at all ages, with an age-adjusted incidence of 12.0/1000 person-years compared to MSK (8.7/1000 person-years) and a hazard ratio of 1.7 (95% CI 1.08-2.71) for SLE. Increasing age and reduced functional status were independent predictors of HZ. In SLE, prednisone and mycophenolate mofetil use conferred additional risk. SLE had the lowest HZ vaccination rates among age-eligible subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257402     DOI: 10.1177/0961203312470186

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

Review 1.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.

Authors:  Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Jessica M Franklin; Daniel H Solomon; Karen H Costenbader; Seoyoung C Kim
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

3.  Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.

Authors:  C Rondaan; C C van Leer; S van Assen; H Bootsma; K de Leeuw; S Arends; N A Bos; J Westra
Journal:  Lupus       Date:  2018-04-18       Impact factor: 2.911

4.  The case for Zostavax vaccination in systemic lupus erythematosus.

Authors:  Abigail R Cogman; Eliza F Chakravarty
Journal:  Vaccine       Date:  2013-06-03       Impact factor: 3.641

5.  Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis.

Authors:  Candace H Feldman; Linda T Hiraki; Wolfgang C Winkelmayer; Francisco M Marty; Jessica M Franklin; Seoyoung C Kim; Karen H Costenbader
Journal:  Arthritis Rheumatol       Date:  2015-06       Impact factor: 10.995

Review 6.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

7.  Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.

Authors:  Huifeng Yun; Shuo Yang; Lang Chen; Fenglong Xie; Kevin Winthrop; John W Baddley; Kenneth G Saag; Jasvinder Singh; Jeffrey R Curtis
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

8.  Herpes zoster vaccination in SLE: a pilot study of immunogenicity.

Authors:  Joel M Guthridge; Abigail Cogman; Joan T Merrill; Susan Macwana; Krista M Bean; Tiny Powe; Virginia Roberts; Judith A James; Eliza F Chakravarty
Journal:  J Rheumatol       Date:  2013-09-15       Impact factor: 4.666

Review 9.  Developments in Varicella Zoster Virus Vasculopathy.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 6.030

10.  CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus.

Authors:  Jin Kyun Park; Ye Ji Lee; Ji Soo Park; Eun Bong Lee; Yeong Wook Song
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.